News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
521,077 Results
Type
Article (44417)
Company Profile (132)
Press Release (476528)
Section
Business (144796)
Career Advice (2390)
Deals (27907)
Drug Delivery (113)
Drug Development (67853)
Employer Resources (148)
FDA (15573)
Job Trends (11934)
News (263356)
Policy (29568)
Tag
Academia (2282)
Alliances (35855)
Alzheimer's disease (1334)
Approvals (15501)
Artificial intelligence (150)
Bankruptcy (302)
Best Places to Work (9162)
Breast cancer (187)
Cancer (1403)
Cardiovascular disease (123)
Career advice (1994)
CAR-T (105)
Cell therapy (299)
Clinical research (54317)
Collaboration (472)
Compensation (300)
COVID-19 (2560)
C-suite (118)
Data (1338)
Diabetes (186)
Diagnostics (5125)
Drug pricing (106)
Earnings (57317)
Employer resources (136)
Events (75424)
Executive appointments (408)
FDA (16311)
Funding (413)
Gene therapy (222)
GLP-1 (686)
Government (3805)
Healthcare (14756)
Infectious disease (2657)
Inflammatory bowel disease (106)
Interviews (445)
IPO (13867)
Job creations (3153)
Job search strategy (1661)
Layoffs (463)
Legal (6914)
Lung cancer (212)
Manufacturing (205)
Medical device (11097)
Medtech (11100)
Mergers & acquisitions (14250)
Metabolic disorders (528)
Neuroscience (1684)
NextGen: Class of 2025 (4976)
Non-profit (3161)
Northern California (1692)
Obesity (309)
Opinion (196)
Parkinson's disease (101)
Patents (128)
People (42094)
Phase I (16227)
Phase II (23514)
Phase III (19337)
Pipeline (601)
Postmarket research (2203)
Preclinical (6543)
Radiopharmaceuticals (204)
Rare diseases (284)
Real estate (4248)
Regulatory (20436)
Research institute (2052)
Resumes & cover letters (401)
Southern California (1421)
Startups (2738)
United States (14371)
Vaccines (641)
Weight loss (242)
Date
Today (168)
Last 7 days (829)
Last 30 days (2005)
Last 365 days (31275)
2025 (1218)
2024 (31417)
2023 (34983)
2022 (45057)
2021 (48498)
2020 (45511)
2019 (36210)
2018 (27397)
2017 (27804)
2016 (25803)
2015 (27974)
2014 (21776)
2013 (17792)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (667)
Arizona (144)
Asia (30700)
Australia (5375)
California (3725)
Canada (1138)
China (275)
Colorado (167)
Connecticut (194)
Europe (74510)
Florida (537)
Georgia (120)
Illinois (326)
Indiana (184)
Maryland (626)
Massachusetts (2897)
Michigan (140)
Minnesota (255)
New Jersey (1054)
New York (1024)
North Carolina (708)
Northern California (1692)
Ohio (120)
Pennsylvania (856)
South America (1033)
Southern California (1421)
Texas (519)
Washington State (384)
521,077 Results for "topotarget a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
4 min read
·
Heather McKenzie
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
The report comes just two days after Novartis announced its own Parkinson’s drug failure.
December 19, 2024
·
1 min read
·
Annalee Armstrong
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
December 10, 2024
·
2 min read
·
Tristan Manalac
Drug shortages
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded pharmacies are still making them. That’s unprecedented.
November 26, 2024
·
4 min read
·
Ben Hargreaves
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
GLP-1
Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
December 9, 2024
·
6 min read
·
Heather McKenzie
Drug shortages
FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period
After a couple months of uncertainty, the FDA has told compounding pharmacies that they have 60 to 90 days before the agency will enforce rules to stop their production of GLP-1s.
December 19, 2024
·
3 min read
·
Tristan Manalac
Regulatory
Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
January 13, 2025
·
5 min read
·
Kate Goodwin
Business
Trials and Capital: Women’s Health and APAC’s Healthcare Revolution
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.
January 2, 2025
·
1 min read
·
Lori Ellis
1 of 52,108
Next